Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

The role of glycogen synthase kinase-3beta in schizophrenia.

Koros E, Dorner-Ciossek C.

Drug News Perspect. 2007 Sep;20(7):437-45. Review.

PMID:
17992266
2.

Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease.

Golpich M, Amini E, Hemmati F, Ibrahim NM, Rahmani B, Mohamed Z, Raymond AA, Dargahi L, Ghasemi R, Ahmadiani A.

Pharmacol Res. 2015 Jul;97:16-26. doi: 10.1016/j.phrs.2015.03.010. Epub 2015 Mar 28. Review.

PMID:
25829335
3.

Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action.

Freyberg Z, Ferrando SJ, Javitch JA.

Am J Psychiatry. 2010 Apr;167(4):388-96. doi: 10.1176/appi.ajp.2009.08121873. Epub 2009 Nov 16. Review.

4.
5.

Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.

Gould TD, Manji HK.

Neuropsychopharmacology. 2005 Jul;30(7):1223-37. Review.

6.

Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis.

Kusumi I, Boku S, Takahashi Y.

Psychiatry Clin Neurosci. 2015 May;69(5):243-58. doi: 10.1111/pcn.12242. Epub 2014 Nov 6. Review.

7.

The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature.

Costemale-Lacoste JF, Guilloux JP, Gaillard R.

Encephale. 2016 Apr;42(2):156-64. doi: 10.1016/j.encep.2016.02.003. Epub 2016 Mar 16. Review.

PMID:
26995153
8.

Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection.

Li X, Bijur GN, Jope RS.

Bipolar Disord. 2002 Apr;4(2):137-44. Review.

9.

Low GSK-3beta in schizophrenia as a consequence of neurodevelopmental insult.

Kozlovsky N, Nadri C, Agam G.

Eur Neuropsychopharmacol. 2005 Jan;15(1):1-11. Review.

PMID:
15572268
10.

Glycogen synthase kinase 3beta as a target for the therapy of shock and inflammation.

Dugo L, Collin M, Thiemermann C.

Shock. 2007 Feb;27(2):113-23. Review. Erratum in: Shock. 2007 Jun;27(6):709.

PMID:
17224784
11.

Glycogen synthase kinase-3β (GSK-3β) and its dysregulation in glioblastoma multiforme.

Atkins RJ, Stylli SS, Luwor RB, Kaye AH, Hovens CM.

J Clin Neurosci. 2013 Sep;20(9):1185-92. doi: 10.1016/j.jocn.2013.02.003. Epub 2013 Jun 12. Review.

PMID:
23768967
12.
13.

Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer.

Walz A, Ugolkov A, Chandra S, Kozikowski A, Carneiro BA, O'Halloran TV, Giles FJ, Billadeau DD, Mazar AP.

Clin Cancer Res. 2017 Apr 15;23(8):1891-1897. doi: 10.1158/1078-0432.CCR-15-2240. Epub 2017 Jan 4. Review.

PMID:
28053024
14.

Glycogen synthase kinase-β3 in ischemic neuronal death.

Hanumanthappa P, Densi A, Krishnamurthy RG.

Curr Neurovasc Res. 2014;11(3):271-8. Review.

PMID:
24845601
15.

GSK-3β activity and hyperdopamine-dependent behaviors.

Li YC, Gao WJ.

Neurosci Biobehav Rev. 2011 Jan;35(3):645-54. doi: 10.1016/j.neubiorev.2010.08.001. Epub 2010 Aug 18. Review. Erratum in: Neurosci Biobehav Rev. 2013 Mar;37(3):549.

16.

The Wnt/frizzled/GSK-3 beta pathway: a novel therapeutic target for cardiac hypertrophy.

Blankesteijn WM, van de Schans VA, ter Horst P, Smits JF.

Trends Pharmacol Sci. 2008 Apr;29(4):175-80. doi: 10.1016/j.tips.2008.01.003. Epub 2008 Mar 14. Review.

PMID:
18342376
17.

[Role of glycogen synthase kinase-3β in the pathogenesis of mental disorders].

Ivanova SA, Losenkov IS, Bokhan NA.

Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(6):93-100. Review. Russian.

PMID:
25075421
18.

[Schizophrenia, neurodevelopment and glycogen synthase kinase-3].

Nadri C, Kozlovsky N, Agam G.

Harefuah. 2003 Sep;142(8-9):636-42, 644. Review. Hebrew.

PMID:
14518171
19.

Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDS.

Dewhurst S, Maggirwar SB, Schifitto G, Gendelman HE, Gelbard HA.

J Neuroimmune Pharmacol. 2007 Mar;2(1):93-6. Epub 2006 Dec 16. Review.

PMID:
18040831
20.

Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of Type 2 diabetes.

MacAulay K, Woodgett JR.

Expert Opin Ther Targets. 2008 Oct;12(10):1265-74. doi: 10.1517/14728222.12.10.1265 . Review.

Supplemental Content

Support Center